Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer.

Sereno, María; Higuera, Oliver; Cruz Castellanos, Patricia; Falagan, Sandra; Mielgo-Rubio, Xabier; Trujillo-Reyes, Juan Carlos; Couñago, Felipe

Sereno, María; Higuera, Oliver; Cruz Castellanos, Patricia; Falagan, Sandra; Mielgo-Rubio, Xabier; Trujillo-Reyes, Juan Carlos; Couñago, Felipe.

Afiliación

Sereno M; Medical Oncology Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes 28702, Madrid, Spain. mariasereno75@gmail.com.
Higuera O; Medical Oncology Department, Hospital Universitario La Paz, Madrid 28046, Spain.
Cruz Castellanos P; Medical Oncology Department, Hospital Universitario La Paz, Madrid 28046, Spain.
Falagan S; Medical Oncology Department, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes 28702, Madrid, Spain.
Mielgo-Rubio X; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Alcorcón 28922, Madrid, Spain.
Trujillo-Reyes JC; Department of Thoracic Surgery, Hospital de la Santa Creu I Sant Pau, Barcelona 08029, Catalonia, Spain.
Couñago F; Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón 28223, Madrid, Spain.

World J Clin Oncol ; 12(12): 1182-1192, 2021 Dec 24.

Article en En | MEDLINE | ID: mdl-35070737

Palabras clave

Anti- programmed cell death protein; Anti-programmed cell death ligand 1; Combo; Immunotherapy combinations; Non-small cell lung cancer; anti-CTLA-4; anti-TIGIT

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google